Ajooni Biotech Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
AJOONI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajooni Biotech has submitted a statement to NSE regarding deviation(s) or variation(s) in the use of funds raised from the market, as required under SEBI's Listing Obligations and Disclosure Requirements (Reg. 32). This filing is mandatory for companies that raised money through a public issue, rights issue, or preferential allotment, and the company is reporting that the actual use of proceeds differs from what was originally disclosed to shareholders. Specifics of the amount involved, the original purpose, and the new purpose of the funds are not available in this headline. Investors would need to view the full filing on the NSE/BSE corporate announcements page or the company's website for exact details. Such filings are routine compliance disclosures, but deviations can sometimes raise questions about fund deployment discipline.
For retail investors, this is a yellow-flag filing worth checking — it means the company used raised money differently than originally promised, which could be benign (operational reasons) or a concern (poor planning or shifting priorities). Watch for the actual deviation amount and reasoning in the full document before drawing conclusions.